A preprocedural risk score predicts acute kidney injury following primary percutaneous coronary intervention.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 08 2021
Historique:
revised: 23 06 2020
received: 28 02 2020
accepted: 19 07 2020
pubmed: 17 8 2020
medline: 21 10 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

Reliable preprocedural risk scores for the prediction of Contrast-Induced Acute Kidney Injury (CI-AKI) following Percutaneous Coronary Intervention (pPCI) in patients with ST-elevation myocardial infarction (STEMI) are lacking. Aim of this study was to derive and validate a preprocedural Risk Score in this setting. Two prospectively enrolled patient cohorts were used for derivation and validation (n = 3,736). CI-AKI was defined as creatinine increase ≥0.5 mg/dl <72 h postpPCI. Odds ratios from multivariable logistic regression model were converted to an integer, whose sum represented the Risk Score. Independent CI-AKI predictors were: diabetes, Killip class II-III (2 points each), age > 75 years, anterior MI (3 points), Killip class IV (4 points), estimated GFR < 60 ml/min/1.73m Among STEMI patients, a simple preprocedural Risk Score accurately and reproducibly predicted the risk of CI-AKI, identifying ¼ of patients with a seven-fold risk and 1/10 of patients with a 20-fold risk. This knowledge may help tailored strategies, including delaying revascularization of nonculprit vessels in patients at high risk of CI-AKI.

Sections du résumé

BACKGROUND
Reliable preprocedural risk scores for the prediction of Contrast-Induced Acute Kidney Injury (CI-AKI) following Percutaneous Coronary Intervention (pPCI) in patients with ST-elevation myocardial infarction (STEMI) are lacking. Aim of this study was to derive and validate a preprocedural Risk Score in this setting.
METHODS
Two prospectively enrolled patient cohorts were used for derivation and validation (n = 3,736). CI-AKI was defined as creatinine increase ≥0.5 mg/dl <72 h postpPCI. Odds ratios from multivariable logistic regression model were converted to an integer, whose sum represented the Risk Score.
RESULTS
Independent CI-AKI predictors were: diabetes, Killip class II-III (2 points each), age > 75 years, anterior MI (3 points), Killip class IV (4 points), estimated GFR < 60 ml/min/1.73m
CONCLUSIONS
Among STEMI patients, a simple preprocedural Risk Score accurately and reproducibly predicted the risk of CI-AKI, identifying ¼ of patients with a seven-fold risk and 1/10 of patients with a 20-fold risk. This knowledge may help tailored strategies, including delaying revascularization of nonculprit vessels in patients at high risk of CI-AKI.

Identifiants

pubmed: 32797716
doi: 10.1002/ccd.29176
doi:

Substances chimiques

Contrast Media 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-205

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
Narula A, Mehran R, Weisz G, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35:1533-1540.
Anzai A, Anzai T, Naito K, et al. Prognostic significance of scute kidney injury after reperfused ST-elevation myocardial infarction: synergistic acceleration of renal dysfunction and left ventricular remodeling. J Card Fail. 2010;16:381-389.
Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. BMJ. 2015;351:h4395.
Marenzi G, Cosentino N, Moltrasio M, et al. Acute kidney injury definition and in-hospital mortality in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(7):1-8.
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649-652.
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44:1393-1399.
Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780-1785.
Inohara T, Kohsaka S, Abe T, et al. Development and validation of a pre-percutaneous coronary intervention risk model of contrast-induced acute kidney injury with an integer scoring system. Am J Cardiol. 2015;115:1636-1642.
De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
Pyxaras SA, Sinagra G, Mangiacapra F, et al. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. Am J Cardiol. 2013;111:684-688.
Liu Y, Liu YH, Chen JY, et al. A simple pre-procedural risk score for contrast-induced nephropathy among patients with chronic total occlusin undergoing percutanepus coronary intervention. Int J Cardiol. 2015;180:69-71.
Gurm HS, Seth M, Kooiman J, Share D. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2013;61:2242-2248.
Duan C, Cao Y, Liu Y, et al. A new preprocedure risk score for predicting contrast-induced acute kidney injury. Can J Cardiol. 2017;33:714-723.
Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619.
Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
Lee-Lewandrowski E, Chang C, Gregory K, Lewandrowski K. Evaluation of rapid point-of-care creatinine testing in the radiology service of a large academic medical center: impact on clinical operations and patient disposition. Clin Chim Acta. 2012;413:88-92.
You JS, Chung YE, Park JW, et al. The usefulness of rapid point-of-care creatinine testing for the prevention of contrast-induced nephropathy in the emergency department. Emerg Med J. 2013;30:555-558.
Lindsay J, Canos DA, Apple S, Pinnow E, Aggrey GK, Pichard AD. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol. 2004;94:786-789.
Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115-1123.
Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1-138.
Caspi O, Habib M, Cohen Y, Kerner A, Roguin A, Abergel E, Boulos M, Kapeliovich MR, Beyar R, Nikolsky E, Aronson D. Acute kidney injury after primary angioplasty: is contrast-induced nephropathy the culprit? J Am Heart Assoc. 2017;6(6):e005715.

Auteurs

Stefano Buratti (S)

Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy.

Gabriele Crimi (G)

Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
IRCCS Italian Cardiovascular Network & Department of Internal Medicine, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Interventional Cardiology Unit, Cardio-Thoraco Vascular Department (DICATOV) Genova, Genoa, Italy.

Alberto Somaschini (A)

Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy.

Stefano Cornara (S)

Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy.

Rita Camporotondo (R)

Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Nicola Cosentino (N)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marco Moltrasio (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Mara Rubino (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Monica De Metrio (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Ivana Marana (I)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Stefano De Servi (S)

Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy.
Division of Cardiology, IRCCS Multimedica, Sesto San Giovanni (MI), Milan, Italy.

Giancarlo Marenzi (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Gaetano M De Ferrari (GM)

Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Facoltà di Medicina e Chirurgia, Cardiology, Università degli Studi di Torino, Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH